Endometriosis Market Size is USD 1.43 Billion in 2026

The global endometriosis market, valued at USD 1.36 billion in 2025, is projected to reach approximately USD 2.19 billion by 2035, growing at a compound annual growth rate (CAGR) of 4.85%. This growth reflects increasing awareness, advancements in treatment options, and rising healthcare investments.

Endometriosis Market Statical Scope

The endometriosis market is experiencing robust growth driven by growing disease awareness and enhanced diagnosis rates among women of reproductive age. Awareness campaigns organized by public health departments and NGOs also play an important role. Beyond therapeutic innovation, increased awareness of endometriosis is contributing to the higher diagnosis rates. Government support for women's health and specific guidelines for endometriosis care further contribute to increased awareness. The endometriosis market is poised for significant expansion because of rising funding for research and development.

Endometriosis Market Share, By Region, 2025

• North America- Leading region in the endometriosis market, driven by high prevalence, advanced healthcare infrastructure, and high diagnosis rates.
• Europe- Fastest growing market for endometriosis, driven by rising awareness and demand for new therapies.
• Asia Pacific- Notably growing region in the endometriosis market, rising prevalence of the condition and enhanced awareness regarding the disease.
• LAMEA: Emerging market for endometriosis, driven by the growing healthcare sector.

Endometriosis Market Share, By Type, 2025

• Superficial peritoneal lesion- Growth of this segment is owing to an increase in the prevalence of superficial peritoneal lesions.
• Endometrioma- A significant part of the market focuses on ovarian cysts caused by the condition.
  Deeply infiltrating endometriosis- this segment involves the penetration of endometrial-like tissue into the deeper layers of organs within the pelvic cavity.

Endometriosis Market Share, By Treatment, 2025

• Pain medication- It includes NSAIDs like ibuprofen and naproxen for symptomatic relief of inflammation and cramps.
• Hormone birth control- Demand is increasing because of efficacy in suppressing estrogen to manage pain and lesion growth.
• Gonadotropin-releasing hormone (GNRH) analogues- The segment includes drugs like leuprorelin, goserelin, triptorelin, driven by high efficacy in suppressing ovarian function and pain.

Endometriosis Market Share, By Route of Administration, 2025

• Oral- This route is preferred because of convenience and ease.
• Parenteral- Increasing focus on advanced treatment options for pain management increasing the demand for parenteral.

Endometriosis Market Share, By End User, 2025

• Hospitals- Hospitals are primary providers for endometriosis, particularly for surgical interventions.
• Homecare- This segment is growing because of patient comfort and provides cost-effective, personalized management.
• Specialty centres- Mainly focus on delivering targeted, multidisciplinary, and expert care.

Endometriosis Market Share, By Distribution Channel, 2025

• Hospital pharmacy- They offer specialized, and often expensive, medications directly to patients.
• Online pharmacy- online pharmacies are preferred due to convenience, privacy, and easier price comparisons.
• Retail pharmacy- They provide as the primary dispensing point for hormonal therapies and pain management medications.

Endometriosis Market Share, By Region, 2025 (%)

• LAMEA (10%) — Region with limited access to specialized treatments for endometriosis and relatively low awareness of the condition.
• Asia Pacific (20%) — Emerging market where endometriosis awareness is growing, and treatment options are expanding, particularly in urban centers.
• Europe (30%) — Mature market with high access to advanced treatments, significant research, and high awareness of endometriosis.
• North America (40%) — Largest market with the highest availability of treatments, widespread healthcare access, and significant awareness of the condition.

Endometriosis Market Share, By Treatment, 2025 (%)

• Aromatase Inhibitors (10%) — Medications that reduce estrogen production to help manage endometriosis symptoms by lowering estrogen levels.
• Others (10%) — Alternative treatment options for endometriosis that don't fall under the main categories, including lifestyle modifications and surgical approaches.
• Gonadotropin-Releasing Hormone (GnRH) Analogues (15%) — Drugs that suppress ovarian hormone production, temporarily inducing a menopause-like state to reduce endometriosis symptoms.
• Hormone Birth Control (25%) — Oral contraceptives or other hormonal treatments used to regulate the menstrual cycle and manage endometriosis symptoms.
• Pain Medication (40%) — Medications such as NSAIDs (nonsteroidal anti-inflammatory drugs) used to manage pain associated with endometriosis.

Endometriosis Market Share, By Type, 2025 (%)

• Deeply Infiltrating Endometriosis (20%) — A severe form of endometriosis where the tissue deeply invades the organs and surrounding tissues.
• Endometrioma (25%) — Cysts formed when endometrial tissue grows inside the ovaries, commonly known as "chocolate cysts."
• Others (25%) — Other forms of endometriosis not covered by the common categories, including rare types and atypical presentations.
• Superficial Peritoneal Lesion (30%) — A less severe form of endometriosis where tissue grows on the peritoneum, often causing pelvic pain.

Tuberculin Skin Test Market Companies

• Akorn, Incorporated 
• Pfizer Inc. 
• GlaxoSmithKline plc 
• Novartis AG 
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi 
• Boehringer Ingelheim International GmbH.
• AstraZeneca 
• Johnson & Johnson Private Limited 
• Bayer AG 
• Merck & Co., Inc. 
• Prestige Consumer Healthcare Inc. 
• F. Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company 
• Almirall, S.A.
• Zenomed Healthcare Private Limited
• Cadila Pharmaceuticals 
• Astellas Pharma Inc. 
• Eli Lilly and Company

Endometriosis Market Segmentation

By Type

• Superficial peritoneal lesion
• Endometrioma
• Deeply infiltrating endometriosis
• Others

By Treatment

• Pain medication
• Hormone birth control
• Gonadotropin-releasing hormone (GNRH) analogues
• Aromatase inhibitors
• Others

By Route of administration

• Oral
• Parenteral
• Others

By End users

• Hospitals
• Homecare
• Speciality centres
• Others

By Distribution channel

• Hospital pharmacy
• Online pharmacy
• Retail pharmacy

By Region

• North America
• Europe
• Asia Pacific
• LAMEA